Immutep Ltd., a late-stage immunotherapy company, has announced the successful attainment of a grant from the Polish government for its EFTISARC-NEO Phase II trial. This trial evaluates the combination of eftilagimod alfa (efti) with radiotherapy and KEYTRUDA® (pembrolizumab) in the treatment of resectable soft tissue sarcoma $(STS.UK)$. The funding, awarded by the Polish Medical Research Agency program, supports this innovative study, which has shown promising results by exceeding its primary endpoint of tumour hyalinization/fibrosis. This development highlights the potential of the novel combination therapy in addressing the high unmet medical need in STS, an aggressive orphan cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.